OmniAb Inc. (OABI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

OmniAb Inc. (OABI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.25

0.06 (1.88%)

At close: Jan 15, 2025, 12:49 PM

undefined% (undefined)

Bid	3.24
Market Cap	392.69M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.62
PE Ratio (ttm)	-5.23
Forward PE	n/a
Analyst	Buy

Ask	3.25
Volume	120,490
Avg. Volume (20D)	460,116
Open	3.30
Previous Close	3.19
Day's Range	3.23 - 3.37
52-Week Range	3.19 - 6.55
Beta	undefined

About OABI

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been geneti...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 30, 2021

Employees 106

Stock Exchange NASDAQ

Ticker Symbol OABI

Website https://www.omniab.com

Analyst Forecast

According to 4 analyst ratings, the average rating for OABI stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 177.35% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

OmniAb Inc. is scheduled to release its earnings on Mar 19, 2025, during market hours.
Analysts project revenue of $11.27M, reflecting a 133.72% YoY growth and earnings per share of -0.11, making a -21.43% decrease YoY.

Why Price Moved

2 months ago · Source

-9.35%

OmniAb shares are trading lower after the company ... Unlock content with Pro Subscription

News

1 month ago · businesswire.com

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeut...

2 months ago · seekingalpha.com

OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript

OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer...

2 months ago · zacks.com

OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.